Clinical Trial

A Phase II Clinical Study to Evaluate the Efficacy and Safety of Technetium [99mtc]-H7ND Injection in the Diagnosis of Peritoneal Metastasis of Gastrointestinal Malignant Tumor.

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 6, 2025 (before its estimated September 2025 completion). Its status may not reflect the trial's current state.
Summary
The main purpose of this study is to evaluate the effectiveness of technetium \[99mTc\]-H7ND injection in the diagnosis of peritoneal metastasis of gastrointestinal malignant tumor. Objective: To evaluate the safety of technetium \[99mTc\]-H7ND injection in the diagnosis of peritoneal metastasis of gastrointestinal malignant tumor. Objective: To explore the diagnostic threshold of technetium \[99mTc\]-H7ND injection for peritoneal metastasis of gastrointestinal malignant tumor.
Trial Details
NCT Number NCT07107633
Lead Sponsor Jiaxing Pharmadax Genesis Pharmaceutical Technology Co.,Ltd.
Conditions Solid Tumor, Peritoneal Metastasis
Enrollment 90 participants
Start Date 2025-03-12
Primary Completion 2025-09 (estimated)
Study Completion 2025-09 (estimated)
Updated on ClinicalTrials.gov 2025-08-06